Biotech | December 14, 2021
Moderna to set up mRNA vaccine manufacturing facility in Australia
Up to 100 million mRNA vaccine doses could be produced in Australia each year
Up to 100 million mRNA vaccine doses could be produced in Australia each year
The company will manufacture a cancer immunotherapy product from 2022
GCC Biotech is manufacturing the kits on a public-private partnership (PPP) model
Phase 1 study of quadrivalent flu vaccine (mRNA-1010) successfully boosted titers against all four strains in older and younger adults, even at lowest dose; no significant safety concerns were observed
KOREA PACK and concurrent event ICPI Week (Int’l Cosmetic and Pharmaceutical Industry Week) will be held as hybrid events in 2022
The platform’s technology works as a compression algorithm for molecular testing
According to the companies’ preliminary data, a third dose provides a similar level of neutralizing antibodies to Omicron as is observed after two doses against wild-type and other variants that emerged before Omicron
Organised by the Indian Stroke Association, it has attracted over 800 doctors from India and overseas
_256_384.jpg)
Ind-Ra expects IPM revenue growth of over 12% yoy for FY22.
Data builds on promising signal published last week, underscoring the importance of sotrovimab for early treatment of COVID-19
Subscribe To Our Newsletter & Stay Updated
